F10 and autoimmune polyendocrinopathy: The International Society on Thrombosis and Haemostasis (ISTH), the European Medicines Agency (EMA), the European League Against Rheumatism (EULAR), and the British Society of Hematology (BSH) did not recommend the use of FXa inhibitors in APS patients, especially those with triple positive aPL (8–11).